Dmitrij Hristodorov PhD
General Partner
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS).
Kynexis is a precision neuropsychiatry company based in The Netherlands that is built on two key concepts: best-in-class molecules and precision medicine.
Kynexis' lead candidate, KYN-5356, is a potent KAT-II inhibitor, which is positioned to treat patients suffering from cognitive impairment, associated with schizophrenia (CIAS).
Human Health
NL
Gooimeer 2-35
1411 DC Naarden
The Netherlands
US
1000 Massachusetts Ave
Cambridge, MA 02138
Industry
Biotech
Status
Current
Location
The Netherlands
Kynexis is now starting the Phase 2 trial of KYN-5356, its novel first-in-class drug compound being developed for the treatment of Cognition Impairment Associated with Schizophrenia (CIAS), a life-long affliction that hits people early in life and for which no drugs are currently available. Despite being considered a very high-risk endeavor due to many failures of prior drug development attempts in CIAS, Forbion has a clear vision of success that reaches beyond the usual return on investment. Successful development of KYN-5356 will entirely transform the treatment of schizophrenia patients and have a profound effect on their lives. This vision has been instrumental in aligning Forbion and the management team. Forbion has been a committed and steadfast investor throughout the currently tough investment climate, and its unique collaborative style with the team has contributed to the company’s success thus far.Kees Been
CEO KyNexis
2025
Phase 1 First-in-Human studies with Kyn-5356 successfully completed
Forbion team
Tim Lohoff PhD
Principal